Eugen Tausch
Eugen Tausch
Uniklinik Ulm
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Mutations driving CLL and their evolution in progression and relapse
DA Landau, E Tausch, AN Taylor-Weiner, C Stewart, JG Reiter, J Bahlo, ...
Nature 526 (7574), 525-530, 2015
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ...
New England Journal of Medicine 380 (23), 2225-2236, 2019
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ...
Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ...
Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014
Recurrent mutations refine prognosis in chronic lymphocytic leukemia
P Baliakas, A Hadzidimitriou, LA Sutton, D Rossi, E Minga, N Villamor, ...
Leukemia 29 (2), 329-336, 2015
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open …
O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ...
The Lancet Oncology 21 (9), 1188-1200, 2020
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3 …
AD Zelenetz, JC Barrientos, JR Brown, B Coiffier, J Delgado, M Egyed, ...
The Lancet Oncology 18 (3), 297-311, 2017
Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia
JP Sharman, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ...
Journal of Clinical Oncology 37 (16), 1391, 2019
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
J Malcikova, E Tausch, D Rossi, LA Sutton, T Soussi, T Zenz, AP Kater, ...
Leukemia 32 (5), 1070-1080, 2018
Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
E Tausch, W Close, A Dolnik, J Bloehdorn, B Chyla, L Bullinger, H Döhner, ...
Haematologica 104 (9), e434, 2019
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
CD Herling, M Klaumünzer, CK Rocha, J Altmüller, H Thiele, J Bahlo, ...
Blood, The Journal of the American Society of Hematology 128 (3), 395-404, 2016
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ...
Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
E Tausch, C Schneider, S Robrecht, C Zhang, A Dolnik, J Bloehdorn, ...
Blood, The Journal of the American Society of Hematology 135 (26), 2402-2412, 2020
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
P Cramer, J von Tresckow, J Bahlo, S Robrecht, P Langerbeins, ...
The Lancet Oncology 19 (9), 1215-1228, 2018
Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in …
JP Sharman, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ...
Blood, The Journal of the American Society of Hematology 124 (21), 330-330, 2014
Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study
O Al-Sawaf, C Zhang, T Lu, MZ Liao, A Panchal, S Robrecht, T Ching, ...
Journal of Clinical Oncology 39 (36), 4049, 2021
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
A Agathangelidis, A Chatzidimitriou, K Gemenetzi, V Giudicelli, ...
Blood, The Journal of the American Society of Hematology 137 (10), 1365-1376, 2021
First-line venetoclax combinations in chronic lymphocytic leukemia
B Eichhorst, CU Niemann, AP Kater, M Fürstenau, J Von Tresckow, ...
New England Journal of Medicine 388 (19), 1739-1754, 2023
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
O Al-Sawaf, S Robrecht, J Bahlo, AM Fink, P Cramer, J v Tresckow, ...
Leukemia 35 (1), 169-176, 2021
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
H Parker, MJJ Rose-Zerilli, M Larrayoz, R Clifford, J Edelmann, ...
Leukemia 30 (11), 2179-2186, 2016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20